An adaptive FEA method to predict surface quality in hard machining von Wen, Q., Guo, Y.B., Todd, Beth A.

Volltext

Experimental investigation of fuel cell dynamic response and control von Williams, Keith A., Keith, Warren T., Marcel, Michael J., Haskew, Timothy A., Shepard, W. Steve, Todd, Beth A.

Volltext

Study Guide: What Great Teachers Do Differently : Nineteen Things That Matter Most von Whitaker, Todd

Volltext

Polyurethane foams : Effects of specimen size when determining cushioning stiffness von TODD, B. A, SMITH, S. L, VONGPASEUTH, T

Volltext

The impact of subsequent metastasis on survival in Medicare patients with prostate cancer von Li, Tracy, Shore, Neal D., Mehra, Maneesha, Todd, Mary Beth, Saadi, Ryan, Leblay, Gaetan, Griffiths, Robert

Volltext

The impact of subsequent metastasis on medical costs in Medicare patients with prostate cancer von Li, Tracy, Shore, Neal D., Mehra, Maneesha, Todd, Mary Beth, Saadi, Ryan, Leblay, Gaetan, Griffiths, Robert

Volltext

Study Guide: What Great Principals Do Differently: Twenty Things That Matter Most von Whitaker, Todd, Whitaker, Beth, Zoul, Jeffrey

Volltext

Safe Water Evaluations in the Peruvian Amazon von Magee, Andrew, Macdonald, Rebecca, Johnson, Dr. Pauline, Johnson, Dr. Philip, Todd, Dr. Beth

Volltext

Medical resource use and costs from subsequent metastases in patients with prostate cancer initially diagnosed with locoregional disease von Li, Tracy, Shore, Neal D., Mehra, Maneesha, Todd, Mary Beth, Saadi, Ryan, Leblay, Gaetan, Griffiths, Robert I., Aggarwal, Jyoti

Volltext

G-CSF utilization during abiraterone acetate (AA) and cabazitaxel (C) therapy: A retrospective U.S. claims analysis von Mehra, Maneesha, Stellhorn, Robert, Ng, Yvette, Todd, Mary Beth

Volltext

Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC): Subgroup a... von Fukasawa, Satoshi, Suzuki, Hiroyoshi, Sato, Fuminori, Hashine, Katsuyoshi, Hasumi, Hisashi, Matsumoto, Hiroaki, Tsuchiya, Tomohiro, Uemura, Hirotsugu, Oya, Mototsugu, Kanayama, Hiroomi, Kawaguchi, Kazushiro, Noguchi, Hidehisa, Enjo, Kentaro, Tran, Namphuong, Todd, Mary Beth, Fizazi, Karim, Matsubara, Nobuaki

Volltext

Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data von Flaig, Thomas W., Potluri, Ravi C., Ng, Yvette, Todd, Mary Beth, Mehra, Maneesha

Volltext

Abiraterone acetate followed by enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting von Vogelzang, Nicholas J., Asmar, Lina, Tang, Jun, Yap, Mark, Todd, Mary Beth, Ng, Yvette, Mehra, Maneesha, Patt, Debra A.

Volltext

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic h... von Fizazi, Karim, Tran, Namphuong, Fein, Luis Enrique, Matsubara, Nobuaki, Rodríguez Antolín, Alfredo, Alekseev, Boris Y., Ozguroglu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary Beth, Chi, Kim N.

Volltext

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic h... von Fizazi, Karim, Tran, Namphuong, Fein, Luis Enrique, Matsubara, Nobuaki, Rodríguez Antolín, Alfredo, Alekseev, Boris Y., Ozguroglu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary Beth, Chi, Kim N.

Volltext

Identification, characterization, and chemotherapy utilization in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) using real-world data: Retrospective U... von Flaig, Thomas W., Mehra, Maneesha, Stellhorn, Robert, Ng, Yvette, Todd, Mary Beth

Volltext

A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) von Rathkopf, Dana E., Attard, Gerhardt, Efstathiou, Eleni, Yu, Margaret K., Griffin, Thomas W., Todd, Mary Beth, Wu, Daphne, Kheoh, Thian, Zhao, Xin, Saad, Fred

Volltext

An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer... von Li, Tracy, Thompson, Melissa, Todd, Mary Beth, Yu, Margaret K., Kheoh, Thian San, He, Jianming, Saadi, Ryan

Volltext

Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc... von De Bono, Johann Sebastian, Smith, Matthew Raymond, Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric Jay, Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian San, Li, Jinhui, Todd, Mary Beth, Griffin, Thomas W., Ryan, Charles J.

Volltext

Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302 von Flaig, Thomas W., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric Jay, Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary Beth, Griffin, Thomas W., Ryan, Charles J., De Bono, Johann S.

Volltext